drugset / Trial / NCT05715619
Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults.
Timeline
- Start
- 2023-10-25
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Outcome
Outcome not reported
Stopped (Business): “Phase 2a paused due to funding limitations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VRELysin™ | Other / unclassified | 1 ml | Oral |
Indications
No indication recorded.